Vertex Pharmaceuticals Thrives on Higher Sales and Guidance来源:FXEmpire发布于 2026-11-04VRTX's Q3 fiscal 2027 revenue rose 12% YoY to $3.44B, driven by cystic fibrosis and new products like CASGEVY and PALSONIFY.相关标的:VRTX继续访问返回新闻本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。